by Asher Mullard
From Nature Reviews Drug Discovery:
Although biopharma start-up companies have to be laser-focused on translational science, this single-mindedness sometimes comes at the expense of clinical development expertise. The venture capital group Flagship Ventures has now named Michael Rosenblatt as Chief Medical Officer to help its portfolio of companies fill that experience gap. Rosenblatt was Chief Medical Officer at Merck & Co. for 7 years prior to this role, and Dean of Tufts University School of Medicine before that.
He talked with Asher Mullard about his new job, and his novel proposal for how to handle the reproducibility crisis. Read more here.